phone

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 143
  • Category: Pharmaceuticals
  • Country: Global
Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017, provides an overview of the Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline landscape.

Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 9, 5, 11, 1 and 1 respectively.

Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction 5
Global Markets Direct Report Coverage 5
Ventilator Associated Pneumonia (VAP) - Overview 6
Ventilator Associated Pneumonia (VAP) - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 11
Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 21
Achaogen Inc 21
Adenium Biotech ApS 21
Aridis Pharmaceuticals LLC 22
AstraZeneca Plc 22
Bayer AG 23
Cardeas Pharma Corp 23
Destiny Pharma Ltd 24
Dong-A Socio Holdings Co Ltd 24
Lakewood-Amedex Inc 25
MedImmune LLC 25
Meiji Seika Pharma Co Ltd 26
Merck & Co Inc 26
Motif Bio Plc 27
Nabriva Therapeutics AG 27
Polyphor Ltd 28
Shionogi & Co Ltd 28
Tetraphase Pharmaceuticals Inc 29
The Medicines Company 29
Theravance Biopharma Inc 30
Wockhardt Ltd 30
Zavante Therapeutics Inc 31
Ventilator Associated Pneumonia (VAP) - Drug Profiles 32
(amikacin sulfate + fosfomycin) - Drug Profile 32
(avibactam + ceftazidime) - Drug Profile 34
(avibactam sodium + aztreonam lysine) - Drug Profile 39
(cefepime + zidebactam) - Drug Profile 41
(ceftolozane sulfate + tazobactam sodium) - Drug Profile 42
(cilastatin sodium + imipenem + relebactam) - Drug Profile 47
(meropenem+ vaborbactam) - Drug Profile 49
AA-139 - Drug Profile 53
Aerucin - Drug Profile 54
amikacin sulfate - Drug Profile 56
arbekacin - Drug Profile 58
ASN-100 - Drug Profile 59
cefiderocol - Drug Profile 62
EBX-004 - Drug Profile 66
eravacycline - Drug Profile 67
exeporfinium chloride - Drug Profile 74
fosfomycin tromethamine - Drug Profile 76
iclaprim mesylate - Drug Profile 79
lefamulin acetate - Drug Profile 84
Mul-1867 - Drug Profile 89
murepavadin - Drug Profile 91
Nu-2 - Drug Profile 93
Nu-3 - Drug Profile 94
Panaecin - Drug Profile 96
panobacumab - Drug Profile 97
plazomicin sulfate - Drug Profile 99
POL-7001 - Drug Profile 107
Qn-2251 - Drug Profile 108
sodium hypochlorite - Drug Profile 109
suvratoxumab - Drug Profile 110
tedizolid phosphate - Drug Profile 111
telavancin hydrochloride - Drug Profile 119
tosatoxumab - Drug Profile 124
Viritron VDX - Drug Profile 126
Ventilator Associated Pneumonia (VAP) - Dormant Projects 127
Ventilator Associated Pneumonia (VAP) - Discontinued Products 128
Ventilator Associated Pneumonia (VAP) - Product Development Milestones 129
Featured News & Press Releases 129
Appendix 139
Methodology 139
Coverage 139
Secondary Research 139
Primary Research 139
Expert Panel Validation 139
Contact Us 139
Disclaimer 140

List Of Tables


Number of Products under Development for Ventilator Associated Pneumonia (VAP), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Achaogen Inc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Bayer AG, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Destiny Pharma Ltd, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Lakewood-Amedex Inc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune LLC, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co Inc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics AG, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Polyphor Ltd, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co Ltd, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by The Medicines Company, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Theravance Biopharma Inc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Wockhardt Ltd, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Zavante Therapeutics Inc, H2 2017
Ventilator Associated Pneumonia (VAP) - Dormant Projects, H2 2017
Ventilator Associated Pneumonia (VAP) - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Ventilator Associated Pneumonia (VAP), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017, provides an overview

View Report

Medical Ventilators - Medical Devices Pipeline Assessment, 2017 GlobalDatas Medical Devices sector report, Medical Ventilators - Medical Devices Pipeline Assessment, 2017 provides an overview of Medical Ventilators currently in pipeline stage. The

View Report

Ventilator Associated Pneumonia (VAP) -Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Ventilator Associated Pneumonia (VAP). The key objective of the report is to establish

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports